What is the equivalent once‑daily dose of Tresiba (insulin degludec) for a patient currently taking 44 units of NPH insulin?

Converting 44 Units of NPH to Tresiba (Insulin Degludec)

Start with 35 units of Tresiba once daily (80% of the 44-unit NPH dose) to minimize hypoglycemia risk, then titrate based on fasting glucose monitoring.

Conversion Approach

The FDA-approved Tresiba label provides clear guidance for switching from intermediate-acting insulins like NPH 1. The conversion strategy differs between adults and pediatric patients:

For Adults

• Start unit-for-unit: Begin Tresiba at 44 units once daily (same as total daily NPH dose) 1
• This 1:1 conversion is the standard FDA-recommended approach for adults switching from NPH

For Pediatric Patients (1 Year and Older)

• Start at 80% of NPH dose: Begin Tresiba at 35 units once daily 1
• This dose reduction (from 44 to 35 units) specifically minimizes hypoglycemia risk in younger patients

Critical Safety Considerations

Monitor closely for hypoglycemia during the first 2-4 weeks after conversion. Tresiba has fundamentally different pharmacokinetics than NPH:

• Half-life: ~25 hours (vs. 12-16 hours for NPH) 1
• Duration of action: >42 hours at steady state 1, 2
• Steady state: Reached after 3-4 days 1
• Flat, stable profile: Minimal peak-trough variation compared to NPH's pronounced peaks 3

The ultra-long action means Tresiba provides more consistent 24-hour coverage but takes longer to reach equilibrium. NPH's shorter duration and peak effect at 4-8 hours creates a different glucose-lowering pattern.

Titration Protocol

After initiating Tresiba at the converted dose:

1. Wait 3-4 days for steady state before making dose adjustments 1
2. Adjust by 2 units every 3-4 days based on fasting glucose targets 4
3. Reduce dose by 10-20% if unexplained hypoglycemia occurs 4
4. Set individualized fasting plasma glucose goals per current ADA guidelines 4

Why This Matters for Outcomes

Evidence shows Tresiba reduces nocturnal hypoglycemia risk by 26-32% compared to NPH while achieving similar HbA1c control 5, 6. This translates to:

• Lower severe hypoglycemia risk (particularly important for morbidity/mortality reduction)
• More stable glucose levels with coefficient of variation around 20% vs. higher variability with NPH 1, 6
• Flexible dosing window once at steady state (though pediatric patients should maintain consistent timing) 1

Common Pitfalls to Avoid

1. Don't assume immediate equivalence: The different pharmacokinetics mean glucose patterns will shift over the first week
2. Don't make premature dose adjustments: Wait for steady state (3-4 days minimum) before titrating 1
3. Don't forget glucagon prescription: ADA guidelines recommend prescribing emergency glucagon when initiating basal insulin 4
4. Don't ignore injection site rotation: Repeated injections into lipodystrophy areas can cause erratic absorption and hyperglycemia 1

Dosing Formulation Selection

For a 44-unit dose:

• Tresiba U-100 (FlexTouch pen or vial): Delivers 1-unit increments, appropriate for this dose 1
• Tresiba U-200 (FlexTouch pen only): Delivers 2-unit increments; would round to 44 units 1

Either formulation provides equivalent pharmacokinetics at the same unit dose 1.